Chiesi Agrees to Buy KalVista Pharmaceuticals for $1.9 Billion

Chiesi Farmaceutici agreed to acquire US-listed KalVista Pharmaceuticals for about $1.9 billion, marking Chiesi’s biggest acquisition to date. The deal expands Chiesi’s rare immunology portfolio and is a meaningful strategic move in healthcare and biotech M&A. The transaction is likely to support sentiment around both companies, with the clearest impact on KalVista shares and Chiesi’s pipeline strategy.

Analysis

Chiesi Farmaceutici agreed to acquire US-listed KalVista Pharmaceuticals for about $1.9 billion, marking Chiesi’s biggest acquisition to date. The deal expands Chiesi’s rare immunology portfolio and is a meaningful strategic move in healthcare and biotech M&A. The transaction is likely to support sentiment around both companies, with the clearest impact on KalVista shares and Chiesi’s pipeline strategy.